Erlotinib has better efficacy than gefitinib in adenocarcinoma patients without EGFR-activating mutations, but similar efficacy in patients with EGFR-activating mutations

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are an effective treatment for advanced non-small cell lung cancer. The objective of the present study was to compare the efficacy of gefitinib and erlotinib in patients with pulmonary adenocarcinoma, whose tumor EGFR mutation s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: WU, WEN-SHUO, CHEN, YUH-MIN, TSAI, CHUN-MING, SHIH, JEN-FU, CHIU, CHAO-HUA, CHOU, KUN-TA, LAI, SHINN-LIANG, WU, CHIEH-HUNG, LUO, YUNG-HUNG, HUANG, CHU-YUN, LEE, YU-CHIN, PERNG, REURY-PERNG, WHANG-PENG, JACQUELINE
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2012
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3438713/
https://ncbi.nlm.nih.gov/pubmed/22969870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/etm.2011.383
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars